Dialysis and kidney failure in Black patients: what the data demand

Black individuals make up 13% of the U.S. population and 30% of everyone living with kidney failure. The incidence of end-stage renal disease (ESRD) among Black Americans is four times higher than for any other group. That gap is not explained by genetics alone. It compounds APOL1 risk variants, undertreated hypertension, undertreated diabetes, and a care system that refers Black patients to nephrologists later, often after irreversible damage is done.

Three forces converge to drive Black Americans to dialysis. The first is genetic. APOL1 G1 and G2 risk variants, present in roughly 13% of African Americans at the high-risk two-allele genotype, substantially elevate CKD progression risk. In the AASK trial, Black patients in the APOL1 high-risk group reached kidney failure at a rate of 58.1%, versus 36.6% in the low-risk group (hazard ratio 1.88). APOL1 variants were originally protective against African sleeping sickness; that evolutionary advantage carries a kidney cost.

The second force is disease burden. Black adults are more likely to develop both hypertension and type 2 diabetes at younger ages, and both are primary drivers of kidney damage when undertreated. Among Black Americans with ESRD, hypertension is listed as the primary cause at higher rates than for any other racial group. For the full picture of hypertension management, see our guide on high blood pressure in Black men, and for diabetes, our guide on type 2 diabetes in Black adults. APOL1 high-risk variants do not increase the prevalence of diabetic kidney disease on their own, but they do accelerate the rate at which it progresses, making tight glycemic and blood pressure control especially important for Black patients who carry these variants.

The third force is care access and timing. In an observational cohort of more than 56,000 veterans with stage 4 CKD, Black and Hispanic veterans progressed to ESRD at 62 to 79% higher rates after full adjustment, even in a system with equal specialist access. This shows that referral alone does not close the gap: biological factors (including APOL1) and structural inequities continue to drive worse progression in Black patients who do reach nephrology care. Meanwhile, USRDS data confirm that Black patients in predominantly Black zip codes are significantly less likely to receive pre-ESRD nephrology care before reaching dialysis, meaning a large share arrive at kidney failure without the preparation that determines what dialysis options will be available to them. Late referral also means late transplant listing, which compounds the access gap downstream.

Most people starting dialysis in the United States start in-center hemodialysis. That means three sessions per week at a dialysis clinic, each lasting three to five hours, during which a machine filters blood through an artificial membrane to remove waste and fluid. It is effective and well-supported logistically. The downsides are rigid scheduling, fatigue after sessions, dietary restrictions on potassium, phosphorus, and sodium, and strict fluid limits between sessions to prevent dangerous fluid buildup between treatments.

Two home-based alternatives exist and are clinically recommended, especially for patients who can manage them:

• Peritoneal dialysis (PD): Uses the lining of your abdomen as a natural filter. Fluid is instilled and drained through a small catheter, usually at home daily or overnight via a cycling machine. No needles per session, more dietary flexibility, and no fixed clinic schedule. Infection risk at the catheter site and abdomen is the main complication.
• Home hemodialysis (HHD): The same blood-filtering process as in-center HD, done at home on a more frequent schedule (often 5 to 6 days per week). More frequent dialysis removes more waste and fluid per week than the standard three-day schedule, which reduces the physiologic swings that make in-center patients feel drained. Requires training and a caregiver or partner support for setup in most programs.

Only 7.3% of Black kidney failure patients use home-based dialysis, one of the lowest rates among any group in the U.S. The barriers are real: less pre-ESRD education, higher rates of unplanned dialysis starts that push patients straight onto in-center HD with no time to prepare, and practical factors like home space for supplies. But the outcomes data is a reason to push past those barriers. A 2025 analysis of over 15,000 dialysis patients found that home hemodialysis was associated with fewer hospitalizations and fewer days in hospital across all groups, with the benefit most pronounced for Black patients, particularly for infection-related admissions.

A kidney transplant is the best long-term outcome for most patients with kidney failure. Transplant recipients live longer, have better quality of life, and spend less time on dialysis. Black patients are nearly one-third of the national kidney waitlist but face documented barriers at every step: referral for evaluation, placement on the list, and receipt of a living-donor kidney.

In a national study of 439,455 adults initiating dialysis between 2015 and 2019, non-Hispanic Black patients were 14% less likely to be waitlisted for a transplant after adjustment. The disparity was sharpest among the youngest patients: Black adults aged 18 to 29 were 27% less likely to be listed. Medical mistrust, structural racism, and provider referral bias all contribute, with socioeconomic factors explaining only about one-third of the gap. The majority of the disparity remains unexplained by any measured factor.

A specific, correctable source of waitlist disadvantage was only addressed in 2022. For years, kidney function formulas (eGFR) used by transplant centers included a race modifier that inflated estimated kidney function for Black patients, making their kidneys appear healthier than they were. This meant Black patients were often referred for transplant evaluation later and accumulated waitlist credit later than they should have. Research estimated the race variable cost Black patients between 1.3 and 1.9 years of waitlist time. In December 2022, the Organ Procurement and Transplantation Network eliminated the race modifier and implemented a policy to restore lost waiting time. Within six months, more than 6,100 Black candidates received retroactive credit, with a median addition of 1.7 years. The correction matters, but it did not eliminate the broader disparity in referral and listing rates.

Dialysis does not restore full kidney function, but with consistent treatment and a managed diet most people maintain a meaningful quality of life. The main restrictions address what the kidneys can no longer clear: potassium (bananas, oranges, potatoes, tomatoes), phosphorus (dairy, dark sodas, processed foods with phosphate additives), sodium, and total fluid intake. A renal dietitian on your care team sets individual targets. Ask to meet with yours at every care plan review. Boiling and draining high-potassium vegetables reduces their potassium content substantially, which can keep many traditional foods in reach. Home dialysis modalities offer more scheduling flexibility, which makes staying employed and socially active more feasible for many patients.

Two conversations can materially change outcomes for a Black patient on dialysis or approaching it. The first is about modality. Federal law (the ESRC statute and ESRD Network requirements) requires dialysis facilities to provide education on all modality options before or shortly after you start. If you were not offered that education, you can request it. Ask your nephrologist or dialysis social worker: "Am I a candidate for peritoneal dialysis or home hemodialysis? Can you refer me to a home-training program?" If your clinic does not have a home program, you can request a referral to one that does.

The second conversation is about transplant. The OPTN recommends referral to a transplant center when eGFR reaches 20 mL/min or below, and evaluation should begin at CKD stage 4 (eGFR below 30). Preemptive transplantation, receiving a kidney before starting dialysis, has better outcomes than transplant after dialysis initiation. Ask your nephrologist directly: "Has a referral been placed for transplant evaluation? If not, can we place one today?" You can also contact a transplant center directly and request an evaluation appointment. If you want a nephrologist or transplant specialist who understands the specific experience of Black patients with kidney disease, find a Black nephrologist or transplant specialist in our directory.

Kidney care for Black patients benefits from a nephrologist who understands the APOL1 genetic context, the specific dietary and cultural considerations, and the documented barriers to home dialysis and transplant access. If you want a nephrologist or transplant specialist who takes that history seriously, find a Black nephrologist or transplant specialist in our directory. If your current nephrologist has not yet referred you for transplant evaluation and your eGFR is below 30, that conversation starts at your next appointment, not the one after.